YHN Acquisition I Limited

Scope note: YHN was incorporated on Dec 18, 2023. FY2021–FY2022 do not exist. FY2023 is a 14-day stub with no operations, and its figures were not available in the sources reviewed. The tables therefore cover FY2024 and FY2025 (audited, 10-K FY2025), with 2026 interim periods shown separately. All figures are in USD.

Income statement

EBITDA is not meaningful. It equals operating loss because there is no D&A and no interest expense: -286,649 in FY2024 and -1,136,899 in FY2025. Gross, operating, EBITDA and net margins, and revenue CAGR, cannot be calculated because revenue is zero.

Interim results

Sources: 10-Q Q1 2026; 10-Q Q2 2026. Q2 2026 income and cost components were not captured in the sources reviewed. The 0 entries for Q2 2026 trust income and costs mean "not captured", not zero. Q1 2025 costs are derived (trust income minus net income).

Balance sheet

FY2024 cash outside trust and FY2024–FY2025 total assets and equity were not captured in the sources reviewed; the 0 in the FY2024 cash cell means "not captured". Aggregator ROIC.ai shows book value per share of 18.47 (2024) and 3.29 (2025), but these are not reconciled to filings.

Latest balance sheets (10-Q Q1 2026, March 31, 2026; Q2 deficit from 10-Q Q2 2026):

Working capital at Mar 31, 2026 was a deficit of $984,667 (derived: 89,313 minus 1,073,980). Goodwill and intangibles are zero. Net debt equals minus cash, because there is no funded debt; current liabilities include amounts due to related parties, whose itemization was not captured.

Trust account trajectory

The Sept 2026 public share count was not disclosed in sources reviewed; the 0 is a placeholder, not a reported value. Derived only: at a redemption value of about $10.8–$11.2 per share, $7.88M corresponds to roughly 0.70–0.73M public shares.

Cash flow

Operating cash flow was negative in both years. Aggregator free cash flow per share was -0.08 (2024) and -0.15 (2025) on ROIC.ai, not reconciled to filings. Extension deposits of $150,000 (Mar 2026), $150,000 (Jun 2026) and $100,000 (Sep 2026) occurred in FY2026.

Commentary

Earnings drivers. Reported profits reflect trust yield, not business performance. Net income rose from $0.50M in FY2024 (about 3.5 months of trust income) to $1.33M in FY2025 (a full year on about $61M until the December redemptions). Operating costs nearly quadrupled, from $0.29M to $1.14M, as deal costs for the Mingde BCA, the F-4, CSRC work and proxies built up.

Inflection. The December 2025 redemptions removed 58% of the public float (3,464,179 of 6,000,000 shares) and $36.65M of trust. Quarterly trust income fell from $0.64M (Q1 2025) to $0.24M (Q1 2026). Quarterly net income fell from $0.55M to $0.10M. The September 2026 redemptions cut the trust by a further ~71%, to $7.88M. On a trust that size, annual interest at prevailing T-bill yields will be roughly the same as the SPAC's ongoing cost base. Reported earnings should therefore move toward breakeven or losses from Q4 2026.

Liquidity. Cash outside trust fell from $737,704 at IPO to $140,550 (Dec 2025) and $22,788 (Mar 2026). Current liabilities above $1M mean the vehicle depends on sponsor advances. Management states that there is substantial doubt about going concern if no combination closes by the deadline (10-K FY2025; 10-Q Q1 2026).

Management guidance

There is no financial guidance. Management's stated objective is to complete the Mingde combination. Its disclosed path is: F-4 effectiveness, completion of the CSRC filing, an extraordinary general meeting to vote on the seven proposals, PIPE or non-redemption arrangements, and Nasdaq approval of PubCo's listing. The deadline framework runs through June 19, 2027.

Consensus

None available.

Bull case

1. Deal momentum is real. The F-4 is at its second amendment (Jun 23, 2026), CSRC first-round comments are already in hand (Oct 2025), and the sponsor keeps paying for extensions. That points to a credible path to closing within the extra 9 months granted in September 2026.

2. Asymmetric payoff for remaining holders. Each share is backed by trust cash of about $11. If the deal closes, holders who don't redeem also receive 0.1 PubCo share per right. With a tiny post-closing float (derived: under 1M public shares), early trading could be strong, and the earnout thresholds of $15/$20/$25 align Mingde's owners with price performance.

3. Lower HFCAA risk than typical PRC de-SPACs. Both auditors are PCAOB-inspected and outside mainland China and Hong Kong (F-4/A).

Bear case

1. The listing may not survive. YHN failed three Nasdaq standards (MVPHS, MVLS, 400 holders), and the October 14, 2026 cure date passed without a disclosed fix. Continued Nasdaq listing is a closing condition, and an unremedied delisting would break the deal mechanics.

2. Capital base is gone. A $7.88M trust, possibly reduced further by redemptions at the business combination vote, combined with a $1.5M deferred underwriting fee (minimum $500K) and more than $1M of current liabilities, leaves little cash for PubCo. Satisfying the $5,000,001 NTA requirement may need PIPE money that has not been announced.

3. Structural and disclosure red flags. The VIE structure, PRC regulatory discretion, repeated consideration resets ($396M; $200M + $80M; $326M + $70M) and inconsistent dates across filings increase execution risk. Public holders would own only a low-single-digit share of PubCo.

Catalysts and monitorables (next 12 months)

Analyst verdict

YHN Acquisition I Limited should be analysed as a binary event instrument wrapped in a trust account. Ordinary equity tools such as earnings, margins and multiples don't apply. The structure did what it was designed to do: public capital was protected in Treasuries, per-share trust value accreted from $10.05 to about $11, and holders could exit at every extension vote. They exited at scale. About 58% of the float redeemed in December 2025, and the trust lost another ~71% in September 2026. That leaves a vehicle with about $7.9 million of public money, a shareholders' deficit of about $2.8 million, cash outside trust measured in thousands of dollars, and a sponsor that must keep funding the balance.

Against this, the Mingde transaction has real momentum: a twice-amended F-4, CSRC engagement, a fairness opinion and a sponsor who has paid every extension deposit. But the obstacles have grown faster than the progress. Three unresolved Nasdaq deficiencies directly threaten a closing condition. The VIE structure carries well-known PRC regulatory risk. Headline consideration has been restated several times across filings.

For a holder today, the trade-off is simple. Redeeming at the next vote locks in roughly trust value. Staying in for closing adds the 0.1-share right and exposure to a very thin float. The most likely outcomes in our view, ranked qualitatively, are further delay, then a closing on a heavily redeemed basis (possibly after moving to the Nasdaq Capital Market), with outright liquidation a meaningful tail risk. We would treat YHNA as suitable only for SPAC-arbitrage strategies that plan to redeem. Fundamental investors should wait for the definitive proxy, Mingde's audited financials and resolution of the listing status before forming a view on the combined company.